Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases
Abstract The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogen...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2025-12-01
|
| Seri Bilgileri: | npj Precision Oncology |
| Online Erişim: | https://doi.org/10.1038/s41698-025-01191-2 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|